ICCM
IceCure Medical Ltd
ICCM's outlook is improving, though it still trails on the overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ICCM overall, supported by stronger fundamentals.
ICCM Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
ICCM's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ICCM PE Valuation
ICCM has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ICCM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ICCM's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ICCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$6.76 | +$1.62 |
| Q1 2026 | -$7.02 | +$1.52 |
| Q4 2025 | -$7.15 | +$1.79 |
| Q3 2025 | -$7.82 | +$0.77 |
| Q2 2025 | -$8.38 | +$0.47 |
| Q1 2025 | -$8.54 | +$0.99 |
| Q4 2024 | -$8.94 | +$0.67 |
| Q3 2024 | -$8.59 | +$2.25 |
ICCM is still losing money, but far less than before: $6.76 per share over the past year, against $14.07 at its worst in late 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ICCM on earnings quality, reporting a profit while its opponent remains loss making.
ICCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $907K | +73% |
| Q1 2026 | $911K | +26% |
| Q4 2025 | $1.3M | +46% |
| Q3 2025 | $850K | +28% |
| Q2 2025 | $525K | -48% |
| Q1 2025 | $725K | -2.4% |
| Q4 2024 | $875K | -30% |
| Q3 2024 | $662K | +102% |
ICCM's revenue is recovering but still below its 2021 peak: $907,000 last quarter, up 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 488% | +1133 points |
| Q1 2026 | -466% | +38 points |
| Q4 2025 | -330% | +188 points |
| Q3 2025 | -2108% | -1460 points |
| Q2 2025 | -645% | -326 points |
| Q1 2025 | -504% | -13 points |
| Q4 2024 | -517% | -245 points |
| Q3 2024 | -648% | +612 points |
ICCM has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ICCM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ICCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.9M | -$1.1M |
| Q1 2026 | -$4.3M | -$277K |
| Q4 2025 | -$5.5M | -$1.3M |
| Q3 2025 | -$2.7M | +$477K |
| Q2 2025 | -$2.8M | -$464K |
| Q1 2025 | -$4M | -$1.2M |
| Q4 2024 | -$4.2M | -$1.6M |
| Q3 2024 | -$3.2M | +$209K |
ICCM has burned cash in almost every quarter: −$16M over the past year, against −$14M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ICCM on cash generation, producing positive trailing cash flow while its opponent burns cash.
ICCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +634K shares |
| 1 year | +58% | +1.1M shares |
| 3 years | +103% | +1.6M shares |
| 5 years | +223% | +2.1M shares |
| Available history | +554% | +2.6M shares |
ICCM has 3M diluted shares, up 58% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ICCM hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over ICCM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ICCM Net Leverage
ICCM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ICCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.3 | Oversold |
| Stochastic | 1.5 | Oversold |
ICCM's weekly RSI is 24 (oversold) and its Stochastic is 2 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ICCM PE vs Healthcare Sector
ICCM has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ICCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.09 | 36% below |
| 20 week MA | $2.23 | 69% below |
| 50 week MA | $9.11 | 92% below |
| 100 week MA | $20.4 | 97% below |
| 200 week MA | $25.3 | 97% below |
ICCM is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ICCM on trend strength, trading above more of its moving averages.
ICCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $331.5 | $85.2 | -74% |
| 2022 | $85.2 | $42.0 | -51% |
| 2023 | $42.0 | $32.1 | -24% |
| 2024 | $32.1 | $33.6 | +4.7% |
| 2025 | $33.6 | $19.9 | -41% |
| 2026 YTD | $19.9 | $0.70 | -96% |
ICCM has finished lower in four of the last five years. It's down 96% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ICCM on returns for 2026, with the stronger performance.